First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Adial Pharmaceuticals, Inc.

    ADIL · 3 developments mapped · last assessed 2026-09-16

    Market Ontology has mapped 3 macro, policy, and market developments to Adial Pharmaceuticals, Inc. since 2026-08-17. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for ADIL yet, so no modelled value is shown. The ADIL valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run ADIL on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for ADIL. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Adial Pharmaceuticals, Inc. Amends PIPE and Note Exchange Agreements to Reclassify Warrant Liability

      Direct financial restructuring improving balance sheet health and reducing potential future liabilities.

      · Moves balance sheet strength, risk of future dilution from warrant exercise

    • Open question

      Adial Pharmaceuticals, Inc. Follow-On — $32M

      Direct capital infusion and potential dilution from share issuance. The financing provides necessary capital for operations and the Azora acquisition, but the structure (private financing, note conversion) suggests potential for significant share count increase.

      · Moves future capital requirements, dilution impact on per share metrics, risk of future financing rounds

    What changed, by assumption

    Future capital requirements
    • 2026-08-17Adial Pharmaceuticals, Inc. Follow-On — $32M
    Balance sheet strength
    • 2026-09-16Adial Pharmaceuticals, Inc. Amends PIPE and Note Exchange Agreements to Reclassify Warrant Liability
    Probability of success for at177
    • 2026-08-17Adial Pharmaceuticals Completed Acquisition of Azora Therapeutics

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-09-16Share countBullishAutomatic conversion of Series A Preferred Stock into 12,930,617 shares of Common Stock following stockholder vote.1.00
    2026-09-16Net debtBearishLiability-management transactions often reduce gross debt or push maturities out.0.70
    2026-09-16Interest expenseBearishTender/exchange extends maturity profile and typically lowers near-term interest expense.0.70
    2026-08-17Valuation multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.0.70
    2026-08-17Share countBullishPrimary equity issuance increases diluted share count.0.70
    2026-08-17Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-08-17Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-08-17RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-16Adial Pharmaceuticals, Inc. Amends PIPE and Note Exchange Agreements to Reclassify Warrant LiabilityBullish1-3m0.70
    2026-08-17Adial Pharmaceuticals, Inc. Follow-On — $32Mmixed1-3m0.80
    2026-08-17Adial Pharmaceuticals Completed Acquisition of Azora Therapeuticsmixed1-5y0.70